Efung Capital

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

Shineyo Medical specializes in the development and distribution of minimally invasive medical devices for cardiovascular interventions. Their primary focus is on electrophysiology and peripheral intervention treatments, with a key emphasis on providing solutions for atrial fibrillation and varicose veins. The company's flagship product is its venous closure system, which utilizes active devices, interventional catheters, and implant materials to permanently treat varicose veins by sealing superficial veins using vein sealant.

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Huiguan Biology is a developer of super-resolution microscopes for in vivo drug screening.

CATUG Biotechnology specializes in the development and application of innovative biomedical technologies, particularly in the realm of gene therapy and nucleic acid drugs. The company offers comprehensive contract development and manufacturing organization (CDMO) services that span the entire industry chain, from research and development to clinical applications and industrialization. With research and development centers and industrialization bases situated in Suzhou and Wuhan, CATUG is well-equipped to support the drug research and production needs of its clients.

Pregis New Materials is a cold chain technology company that specializes in providing solutions for the safe transportation of biomedical products. The company develops advanced cold-chain logistics products that incorporate dual carbon and temperature control solutions. Utilizing Internet of Things (IoT) technology, Pregis New Materials offers real-time temperature monitoring and control, ensuring that products remain within designated temperature ranges during transit. Additionally, the company focuses on the use of durable materials for temperature control, enhancing the efficiency and safety of transporting sensitive goods. Through its innovative offerings, Pregis New Materials aims to meet the growing demands of clients in various industries requiring reliable cold chain logistics.

Turno is a fintech startup that provides electric vehicle solutions for operators and owners. It helps commercial vehicle operators make the switch to EVs. Turno accomplishes this by offering a diverse range of vehicles from partner OEMs, affordable financing, and battery value guarantees to ensure the best possible return on investment for EV owners. Turno's mission in India is to convert gasoline miles to electric miles. The startup sells EVs manufactured by various brands both online and in physical stores, as well as providing financing options and buying back used batteries.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Nanjing IASO Biotherapeutics is a clinical stage biotechnology company founded in 2017 and based in Nanjing, China. The company specializes in the discovery, development, and commercialization of innovative therapies for cancer, particularly through engineered autologous and allogenic T cell therapies. These therapies are designed to enhance the immune system's ability to recognize and eliminate cancer cells, positioning IASO Biotherapeutics as a key player in the oncology field.

Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.

Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine. Maijing Gene was established in 2015 and is based in Guangzhou, China.

JSD provides medical equipment for hospitals. They provides substitution machines for the medical industry. For inquiries, telephone and email are used.

CellOrigin Biotech is a biotechnology company dedicated to the development of immune cell therapies utilizing induced pluripotent stem cells (iPSCs). The company specializes in creating iPSC-derived innate immune cells aimed at treating solid tumors. Its focus encompasses the research and development of innovative technologies, including gene-manipulated clinical iPSCs and an efficient platform for iPSC differentiation. Additionally, CellOrigin Biotech operates a clinical iPSC bank, which supports its goal of advancing therapeutic solutions through mature stem cell reprogramming techniques.

Westlake Omi combines proteomic big data with artificial intelligence, mass spectrometry-based biological sample digitization technology.

Atom Bioscience is a clinical-stage biotechnology company dedicated to developing innovative therapies for inflammatory and metabolic diseases. The company focuses on conditions such as chronic gout and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and certain cancers. By concentrating on the intersections of metabolism and inflammation, Atom Bioscience aims to provide patients with more effective treatment options for these challenging health issues.

Cloudbreak Therapeutics LLC, established in 2015 and based in Irvine, California, is a biotechnology company specializing in the development of ocular drugs. It focuses on repurposing approved systemic drugs for eye delivery, aiming to treat glaucoma and pterygium diseases efficiently. The company operates a capital-efficient model, utilizing contract research organizations (CROs) to maximize resources for drug development. Its business strategy involves advancing drug candidates through proof-of-concept Phase II clinical trials and subsequently out-licensing global rights for Phase III trials, registration, and commercialization.

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.

BioInno is a China-based company that specializes in biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services. It offers process development and Good Manufacturing Practice (GMP) production services tailored for biotechnology and pharmaceutical companies focused on protein, cell therapy, and gene therapy drugs. By facilitating the introduction of these innovative therapies to both the Chinese and global markets, BioInno positions itself as a key partner in the biopharmaceutical industry, helping clients navigate the complexities of drug development and production.

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Genuine Biotech manufactures drugs for the treatment of viral infection, tumors, and cerebrovascular disorders.

Gensciences is a biopharmaceutical company focused on the research and development of innovative drug therapies, particularly long-acting recombinant proteins. The company specializes in treatments for conditions such as hemophilia, metabolic diseases, and tumors. Gensciences aims to develop drugs that are not only effective and safe but also possess a high success rate, positioning itself as a leader in the global biopharmaceutical sector. Through its commitment to continuous innovation, the company strives to improve patient outcomes by providing advanced therapeutic solutions.

Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

Beijing Biostar Technologies, Ltd., established in 2002, is a biopharmaceutical company based in Beijing, China. It specializes in the development of anti-tumor chemotherapy biopharmaceutical molecules, with a focus on creating innovative small molecule chemical drugs for cancer treatment. The company was founded by a team of Chinese scientists led by Dr. Tang Li and Dr. Qiu Rongguo, who previously worked in the United States. Biostar Technologies pioneered the creation of new anti-cancer drugs based on epothilone in China and its technology is recognized as being at the international advanced level.

3D Medicines is a biopharmaceutical company focused on personalized cancer treatment. Utilizing individual genetic information, they develop tailored medicines to prevent, diagnose, and treat cancer more effectively and safely than traditional one-size-fits-all approaches. Their primary focus is on immuno-oncology drugs, aiming to prolong survival time and improve quality of life for cancer patients. Currently, all their revenue is generated from operations in China.

Jifu Medical is a national high-tech enterprise dedicated to the research, development, production, and sales of advanced medical products specifically for the digestive tract. With a strong emphasis on innovation, the company has established a professional research and development team and an international management platform, leading to the completion of numerous national technological innovation projects and the acquisition of over 100 national patents. Jifu Medical's flagship product line, the "Dasheng" magnetically controlled capsule endoscope system, has been under development for a decade and has received both National Medical Products Administration Class III registration and EU CE certification. These innovations have earned widespread acclaim from medical institutions, particularly for their application in non-invasive intestinal examinations, enhancing diagnostic capabilities for healthcare practitioners.

InnerMedical is a company focused on developing innovative diagnosis and treatment solutions for major diseases, particularly in the areas of digestive tract and respiratory tract tumors, as well as cardiovascular and cerebrovascular diseases. The company specializes in minimally invasive medical imaging technologies, including catheter imaging devices and high-frequency endoscopic machines, which enhance diagnostic accuracy and treatment efficacy. InnerMedical has successfully launched domestic endoscopic ultrasonic diagnostic equipment, electronic endoscopes, and a medical image processing software platform, reflecting its commitment to advancing healthcare through continuous technological innovation.

OBiO Technology is a biotechnology company based in Shanghai that specializes in viral-based gene therapy. It offers comprehensive Contract Research Organization (CRO) services, focusing on the development of gene therapy vectors, gene function research, and drug efficacy studies. The company also provides Contract Development and Manufacturing Organization (CDMO) services, which include process development, testing, and clinical sample GMP production. OBiO Technology supports the research and development of genetic drugs, facilitating advancements in gene therapy through its expertise in both foundational research and practical applications within the biopharmaceutical industry.

SiBionics is a medtech company headquartered in Shenzhen, China, focused on the research, development, and commercialization of active implantable medical devices and medical artificial intelligence. The company specializes in innovative solutions for medical imaging and neuromodulation, striving to create cost-effective products that enhance long-term health monitoring and disease management. SiBionics is developing various advanced technologies, including implanted retinal electrical stimulators, continuous glucose monitoring systems, and screening tools for gastric cancer and chronic diseases. Through the integration of visual coding, artificial intelligence, and medical big data, SiBionics aims to address critical health issues such as retinitis pigmentosa, diabetes, cardiovascular and cerebrovascular diseases, and gastrointestinal tumors, ultimately improving diagnostic and treatment options for these conditions.

Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

OBiO Technology is a biotechnology company based in Shanghai that specializes in viral-based gene therapy. It offers comprehensive Contract Research Organization (CRO) services, focusing on the development of gene therapy vectors, gene function research, and drug efficacy studies. The company also provides Contract Development and Manufacturing Organization (CDMO) services, which include process development, testing, and clinical sample GMP production. OBiO Technology supports the research and development of genetic drugs, facilitating advancements in gene therapy through its expertise in both foundational research and practical applications within the biopharmaceutical industry.

WeMed Medical is a developer of digital angiography machines designed for use in the clinical fields of radiology and cardiology. The company focuses on arranging department operations and conducting training for medical professionals to ensure effective utilization of its products. Additionally, WeMed Medical is involved in the international strategic planning of product research and development, enabling the continuous optimization and upgrading of its offerings. This comprehensive approach allows the company to meet the evolving needs of healthcare providers while enhancing patient care.

Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Zhongyianke Biotech is a company focused on the development and provision of human vaccines. It has successfully launched a flu vaccine and is currently conducting clinical trials for several other vaccines, including a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 patents in China, underscoring its innovation in the biotechnology sector. Zhongyianke operates from its headquarters in Tianjin, complemented by a research and development center in Beijing and a production facility located in Liaoning Province.

Tactiva Therapeutics, LLC is an immuno-oncology company based in Buffalo, New York, specializing in the development of innovative cancer immunotherapies. Founded in 2016, the company focuses on adoptive cell therapy, employing a dual T cell receptor approach that utilizes engineered CD4 and CD8 T cells. This platform aims to generate a durable supply of CD4 cells that exhibit direct anti-tumor activity while also providing sustained helper functions to CD8 T cell-derived effector T cells. Through its advanced therapeutic strategies, Tactiva Therapeutics seeks to enhance the diagnosis and treatment of cancer, addressing the needs of patients with life-threatening diseases.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Lifotronic is a China-based company specializing in the development, production, and sale of physiotherapy and medical devices. The company focuses on therapeutic and rehabilitation products, as well as in vitro diagnostic equipment and supporting reagents. Its innovative offerings, which include technologies such as liquid chromatography, nephelometry, and lateral flow immunoassays, enable healthcare providers to enhance treatment efficacy and improve patient outcomes. Lifotronic aims to contribute to the healthcare sector by providing effective medical treatment and recovery solutions.

Chipscreen is an integrated biotech company based in Shenzhen, specializing in the discovery and development of novel small molecule pharmaceuticals. Established in 2001 as a Sino-foreign joint venture by a group of esteemed Chinese returnees with significant academic and industrial expertise, the company employs a proprietary chemical genomics-based discovery platform to create a diverse portfolio of clinical and preclinical stage programs across various therapeutic areas. Chipscreen emphasizes a science-driven approach to drug discovery, supported by strong capabilities in pipeline development, intellectual property management, and regulatory compliance. The company’s strategy involves generating differentiated drug candidates, which may be developed independently or in collaboration with partners throughout the research, preclinical, and clinical stages.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

Resverlogix Corp. is a late-stage clinical biotechnology company based in Calgary, Canada, focused on developing innovative therapeutics for cardiovascular diseases and related conditions. The company's lead product, apabetalone, is a first-in-class small molecule that selectively inhibits the bromodomain and extra-terminal (BET) proteins, targeting the second bromodomain to influence disease-causing genes. Apabetalone is currently undergoing Phase III clinical trials for various indications, including cardiovascular disease, chronic kidney disease, and neurodegenerative disorders. In addition to apabetalone, Resverlogix is advancing several development programs, including NexVas technologies aimed at plaque regression and vascular inflammation, as well as therapeutic candidates for Alzheimer's disease and fibrotic conditions. The company's research underscores its commitment to addressing significant unmet medical needs through innovative biopharmaceutical solutions.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013, the company focuses on addressing significant unmet medical needs in this area. Its product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, as well as Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain linked to inflammatory and neuropathic conditions. Other candidates include CNTX-6970, also in Phase I for inflammatory pain, and CNTX-2022, a high-concentration topical lidocaine gel in Phase I for various pain types. CNTX-6016 is in pre-clinical stages for chronic neuropathic pain. Centrexion aims to provide patients with safe and effective pain relief options through innovative treatment modalities.

KBP Biosciences is a biotechnology research and development organization focused on creating innovative therapies for unmet medical needs, particularly in the fields of cardiovascular, respiratory, inflammatory, and autoimmune diseases. The company is dedicated to the research, development, and commercialization of novel medicines, leveraging new drug development ideas alongside its own medicinal chemistry expertise. With a strong emphasis on clinical development and regulatory compliance, KBP Biosciences aims to empower healthcare providers by offering effective treatments to improve patient outcomes in areas where existing therapeutic options are limited.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Castdservo provides solutions for the field of robots and intelligent equipment. They serve mobile phone manufacturing, battery manufacturing, metal processing, woodworking engraving, medical treatment, robotics, and other industries.

Shenzhen UniHz Technologies Corporation is a developer of intelligent transportation software and solutions, specializing in urban traffic management. Founded in 2002 and headquartered in Shenzhen, China, the company focuses on research and development in the field of intelligent transportation. It aims to integrate application solutions with product development and manufacturing to enhance traffic management systems. As of November 2020, UniHz operates as a subsidiary of Ping An International Smart City Technology Co., Ltd., further strengthening its capabilities in the smart city sector.

Rainjet is a medical equipment research and development manufacturer. They provide products and services for medical institutions, families, and individuals. The drafting units of the mandatory national pharmaceutical industry standard The psychophysiological lie detector measures, records, and analyses changes in the physiological indicators of the subject.